Revolutionizing Pathogen Detection

Using innovative molecular detection to advance the diagnosis and management of cancer

The Most Extensive Microarray Available For Pathogen Detection

PathoChip technology is a proprietary method of identifying specific microbial signatures associated with cancer. Pathochip can accurately detect pathogens that may cause or complicate a disease, impacting treatment, prognosis, and follow-up.

Learn More

Potential Applications of PathoChip Include:

ENHANCE

Diagnostic Screening

ASSESS

Aggressiveness of Cancer

SELECT

Targeted Treatments + Therapies

MONITOR

for Recurrence

Learn More

About Us

ExcaliVir, a molecular diagnostics company, was formed in 2012 by Dr. Erle Robertson and Dr. James Alwine, researchers from the University of Pennsylvania, Perelman School of Medicine to transform pathogen detection by combining next generation microarray and sequencing. Their passion for research on the relationship between the microbiome and human cancer has led to the development of a unique technology for rapid identification of all known infectious agents associated with human disease.

Contact Us

In the News

Penn Researchers Decode Microbial Signature of Aggressive Form of Breast Cancer

Read More

Penn Medicine Microbiologist Receives $1.4 million to Study Viral Pathogens and Cancer

Read More

View All News

The Potential to Transform Patient Care

Learn how PathoChip quickly identified an unknown pathogen and appropriate treatment for a  hospital patient with acute myelogenous leukemia.

Read the Story